Indications
Arterial hypertension, CHD, heart failure
$20.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: |
Arterial hypertension, CHD, heart failure
of Bisoprolol-Teva is taken orally, without chewing, with a small amount of liquid, in the morning on an empty stomach or during breakfast 1.25-10 mg 1 time a day. The dosage regimen is individual, the dose is increased under the control of blood pressure and pulse.
Arterial hypertension and angina pectoris: 5-10 mg; mild arterial hypertension (dBP less than 105 mm Hg): 2.5 mg; chronic heart failure: 1.25 mg/day (for 1 week), then if well tolerated, the dose is increased to 2.5 mg/day (1 week),3.75 mg/day (1 week),5 mg/day (4 weeks),7.5 mg/day (4 weeks), then 10 mg/day (target dose).
The maximum daily dose for adults is 20 mg.
Hypersensitivity to Bisoprolol-Teva, cardiac conduction disorders, bronchial asthma
Active substance:
bisoprolol fumarate 10 mg;
Auxiliary substances:
croscarmellose sodium (Primerose),
povidone (polyvinylpyrrolidone middle),
pregelatinization starch (starch 1500),
silicon dioxide colloid (Aerosil),
talc, microcrystalline cellulose,
lactose (milk sugar),
magnesium stearate;
the composition of the film shell:
Opadry II (polyvinyl alcohol, partially hydrolyzed, titanium dioxide, talc, macrogol (polyethylene glycol 3350), dye iron oxide (II)).
Active ingredient:
bisoprolol fumarate 10 mg;
Auxiliary substances:
croscarmellose sodium (primellose),
povidone (polyvinylpyrrolidone medium molecular weight),
pregelatinized starch (starch 1500),
colloidal silicon dioxide (aerosil),
talc, microcrystalline cellulose,
lactose (milk sugar),
magnesium stearate;
composition of the film shell:
opadray II (partially hydrolyzed polyvinyl alcohol, titanium dioxide, talc, macrogol (polyethylene glycol 3350), iron oxide (II) dye).
Bisoprolol-Teva is a selective beta-1-adrenoblocker with no intrinsic sympathomimetic activity and no membrane-stabilizing activity. Reduces the activity of renin plasma, reduces the need for myocardial oxygen, reduces heart rate (at rest and during exercise) and cardiac output, while the stroke volume does not significantly decrease. Inhibits AV conduction. It has antianginal and antihypertensive effects. In high doses (200 mg or more) it can cause blockade of beta-2-adrenergic receptors mainly in the bronchi and in vascular smooth muscles.
The hypotensive effect is associated with a decrease in minute blood volume, sympathetic stimulation of peripheral vessels, a decrease in the activity of the renin-angiotensin system (which is more important for patients with initial hypersecretion of renin), restoration of sensitivity in response to a decrease in blood pressure, and an effect on the central nervous system.
The antianginal effect is due to a decrease in the myocardial oxygen demand as a result of a decrease in heart rate and contractility, an elongation of the diastole, and an improvement in myocardial perfusion.
The antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased cAMP content, arterial hypertension), a decrease in the rate of spontaneous excitation of sinus and ectopic pacemakers, and a slowdown in AV conduction (mainly in the antegrade and, to a lesser extent, in the retrograde directions through the AV node) and along additional pathways.
Arterial hypertension, CHD, heart failure
It is possible if the expected effect of therapy in the mother exceeds the potential risk to the fetus and child (adequate and strictly controlled studies of the safety of use in pregnant and lactating women have not been conducted).
Since there is a risk of developing bradycardia, hypotension, hypoglycemia and respiratory disorders (neonatal asphyxia) in newborns, treatment with bisoprolol fumarate should be discontinued 48-72 hours before delivery.
If this is not possible, the newborn should be under close medical supervision for 48-72 hours after birth.
The excretion of bisoprolol fumarate in human milk has not been studied, but since it is secreted into human milk in rats (less than 2%), children should be under medical supervision.
Hypersensitivity to Bisoprolol-Teva, cardiac conduction disorders, bronchial asthma
Nervous system and sensory disorders: Â dizziness (3.5%), insomnia (2.5%), asthenia (1.5%), hypesthesia (1.5%), depression (0.2%), drowsiness, restlessness, paresthesia (feeling cold in the extremities), hallucinations, impaired thinking, concentration, orientation in time and space, balance, emotional lability, tinnitus, conjunctivitis, visual disturbances, decreased secretion of tear fluid, convulsions.
Cardiovascular and blood disorders (hematopoiesis, hemostasis): Â bradycardia (0.5%), arrhythmia, palpitation, AV block, hypotension, heart failure, impaired microcirculation in the myocardium and extremities, intermittent claudication, vasculitis, agranulocytosis, thrombocytopenia, thrombocytopenic purpura.
From the digestive tract: Â diarrhea (3.5%), nausea (2.2%), vomiting (1.5%), dry mouth (1.3%), dyspeptic symptoms, constipation, ischemic colitis, mesenteric artery thrombosis.
Respiratory system disorders: Â cough (2.5%), shortness of breath (1.5%), bronchospasm and laryngospasm, pharyngitis (2.2%), rhinitis (4%), sinusitis (2.2%), respiratory tract infections (5%), respiratory distress syndrome.
From the genitourinary system: Â peripheral edema (3%), decreased libido, impotence, Peyronie’s disease, cystitis, renal colic.
From the side of the skin: Â rash, acne, eczema-like reactions, prurigo, redness of the skin, hyperhidrosis, dermatitis, alopecia.
From the side of metabolism: Â increased concentration of liver enzymes( AST, ALT), hyperglycemia or increased glucose tolerance, hyperuricemia, changes in the concentration of potassium in the blood.
Other services:  pain syndrome (headache-10.9%, arthralgia-2.7%, myalgia, abdominal pain, chest pain — 1.5%, eyes, ears), weight gain.
Amiodarone, diltiazem, verapamil, quinidine drugs, cardiac glycosides, reserpine, and alpha-methyldofa increase the probability of violations of automatism, conduction, and contractility of the heart (mutually).
Concomitant use of dihydropyridine calcium antagonists, especially in patients with latent heart failure, increases the risk of hypotension and decompensation of cardiac activity.
Efficacy is reduced by xanthines and sympathomimetics, rifampicin reduces T1 / 2, ergotamine derivatives potentiate peripheral circulatory disorders. Incompatible with MAO inhibitors.
of Bisoprolol-Teva is taken orally, without chewing, with a small amount of liquid, in the morning on an empty stomach or during breakfast 1.25-10 mg 1 time a day. The dosage regimen is individual, the dose is increased under the control of blood pressure and pulse.
Arterial hypertension and angina pectoris: 5-10 mg; mild arterial hypertension (dBP less than 105 mm Hg): 2.5 mg; chronic heart failure: 1.25 mg/day (for 1 week), then if well tolerated, the dose is increased to 2.5 mg/day (1 week),3.75 mg/day (1 week),5 mg/day (4 weeks),7.5 mg/day (4 weeks), then 10 mg/day (target dose).
The maximum daily dose for adults is 20 mg.
Symptoms: bradycardia, arrhythmia, hypotension, heart failure (difficulty breathing, acrocyanosis, edema), hypoglycemia, in severe cases — collapse.
Treatment: gastric lavage and use of adsorbents, symptomatic therapy: atropine, beta-adrenomimetics (isoprenaline), sedatives (diazepam, lorazepam) and cardiotonic (dobutamine, dopamine, epinephrine, norepinephrine) drugs, cardiac glycosides, diuretics, glucagon, etc. In case of heart block — transvenous stimulation, connection of an artificial pacemaker.
It is possible to change the test results during laboratory tests.
Tablets
At a temperature not exceeding 25 °C
2 years
Bisoprolol
By prescription
Tablets
For adults as directed by your doctor
Heart Failure, Hypertension, Arrhythmia
Reviews
There are no reviews yet